A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This is the first study in human patients with asthma that the sponsor is conducting in order
to evaluate if there are signals that the investigational medication, AXP1275, may be a safe
and effective treatment for asthma. The results of this study may help the sponsor to design
additional studies.